Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
RESEARCH TOOLSreports
Tarsus Pharmaceuticals (TARS) Stock Price & Analysis
149 Followers
TARS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.57 - $40.40
Previous Close$32.85
Volume55.70K
Average Volume (3M)760.09K
Market Cap
$1.24B
Enterprise Value$1.03B
Total Cash (Recent Filing)$227.44M
Total Debt (Recent Filing)$29.82M
Price to Earnings (P/E)-7.1
Beta0.98
Next Earnings
May 07, 2024EPS Estimate
-$1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding34,218,886
10 Day Avg. Volume584,690
30 Day Avg. Volume760,091
Standard Deviation0.19
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.10
Price to Sales (P/S)64.43
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue59.28
Enterprise Value/Gross Profit65.24
Enterprise Value/Ebitda-10.75
Forecast
1Y Price Target
$52.14Price Target Upside57.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Tarsus Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive Phase 2a study results for Tarsus's pipeline drugs indicate potential for future growth and expansion beyond XDEMVY.
Market ExpansionTarsus has secured several new contracts including a major plan, enhancing XDEMVY's market access and future revenue potential.
Product PerformanceXdemvy has been gaining steady traction among eye-care professionals, with utilization expanding rapidly.
Bears Say
Financial PerformanceThe company has a high annualized cash burn rate, indicating a need to manage its capital efficiently to sustain operations.
Market SentimentHigh short interest indicates a significant percentage of market participants are betting against the stock.
Regulatory ConcernsThere's caution due to the FDA's safety concerns regarding neurological adverse reactions in canines related to the class of molecules that TP-05 belongs to.
---
Ownership Overview
34.42% Insiders
9.18% Mutual Funds
10.02% Other Institutional Investors
46.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $12.57 and its highest was $40.40 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Currently, no data Available
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Feb 27, 2024. The company reported -$1.31 earnings per share for the quarter, beating the consensus estimate of -$1.372 by $0.062.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -$1.18.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 37,500,137 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$1.31 in its last earnings report, beating expectations of -$1.372. Following the earnings report the stock price went up 18.275%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Among the largest hedge funds holding Tarsus Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Tarsus Pharmaceuticals’s shares valued at 26M.
---
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.14 (57.52% Upside)
$52.14 (57.52% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 750.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $430.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.04%
12-Months-Change
Fundamentals
Return on Equity
-69.71%
Trailing 12-Months
Asset Growth
16.84%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
---
TARS Earnings Call
Q4 2024
0:00 / 0:00
---
TARS Stock 12 Months Forecast
Average Price Target
$52.14
▲(57.52% Upside)
Technical Analysis
Best Analysts Covering TARS
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+80.84%
reiterated a buy rating 2 months ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +80.84% per trade.
---